Why Is NuScale Power Stock Surging After a Difficult December?

NuScale Power (SMR) endured a brutal end to 2025—shares fell about 61% in the last quarter (including a 29.2% December drop) after a 55% November crash tied to a Q3 loss, equity raises and analyst downgrades—but have surged roughly 41% in January. Shareholders approved an increase in authorized shares from 332 million to 662 million, raising dilution risk, and major holder Fluor plans to divest its entire stake by end-Q2 2026; Bank of America upgraded the stock to neutral on Jan. 9 while cutting its price target to $28 (from $34), which still implies ~40% upside. NuScale’s VOYGR SMR technology (77 MWe per module, up to 12 modules per plant) positions it to benefit from renewed corporate interest in nuclear (e.g., Meta’s 6.6 GW deals), but commercial plants and revenue remain years away, keeping the stock highly speculative.

Analysis

Market structure: Nuclear incumbents (utilities like VST, engineering contractors, and uranium/mining suppliers) are the primary beneficiaries of fresh corporate offtakes (Meta’s 6.6 GW signal). NuScale (SMR) and rivals (Oklo/private; Vistra/VST as utility buyer) compete for offtake contracts, but vendor wins will be dictated by licensing speed, site economics (77 MWe/module × up to 12 modules = ~924 MWe plant scale) and supply‑chain capacity over the next 3–7 years.

Risk assessment: Key tail risks are regulatory delay (NRC licensing slips by 12–36 months), project cost overruns (+30–100% typical in first‑of‑a‑kind reactors), and financial dilution (authorized shares jumped ~100% to 662M and FLR plans to exit by end‑Q2 2026). Near‑term (days–months) volatility will be dominated by Fluor’s selling timeline and any DOE funding/contract announcements; long‑term (2–7 years) value depends on commercialization and steady offtake contracts.

Trade implications: Directional exposure should favor regulated/merchant utilities or contractors with balance‑sheet scale (VST, FLR selectively) and commodity plays (uranium suppliers/URA) over pure‑play SMR equity. For SMR equity, treat as a high‑volatility option on policy and execution: size <2% of portfolio or use option structures to cap downside; expect >50% downside if early projects fail and >2x upside if first plants meet budget and offtakes accelerate.

Contrarian angles: Consensus conflates sector demand with vendor victory—NuScale’s rally may be overdone relative to execution risk; Fluor’s exit is a red flag, not a neutral liquidity event. Historical parallels: first‑of‑a‑kind energy tech (early carbon capture, concentrated solar) often sees 2–4 year hype cycles then rationalization; watch licensing milestones and multi‑party offtakes (corporate + DOE) as true validation.

Key Decisions for Investors

• Establish a tactical long in Vistra (VST) of 2–3% portfolio weight over the next 90 days to capture merchant upside from SMR offtakes; target +15–25% in 12 months, place stop‑loss at 12% below execution price.
• Size a speculative position in NuScale (SMR) at 1%–1.5% of portfolio only via a 12‑month call LEAP (buy calls with ~12‑month expiry) or buy equity on a >20% pullback from the Jan rally; cap max loss at total premium (i.e., no margin) and trim if price exceeds BofA PT of $28 or rallies +40% from entry.
• Execute a pair trade: long VST (2%) / short SMR (1%) to express preference for utility capture of SMR economics while hedging vendor execution risk; target relative outperformance of 15% over 6–12 months, unwind if Fluor divestiture is completed without material share supply (monitor monthly).
• Allocate 0.5% portfolio to uranium exposure (URA or select miners) using a 6–12 month horizon; add if uranium spot price rises >15% (signals tightening) or if DOE/industry procurement announcements occur within 90 days.